Scientists from the Translational Genomics Research Institute (TGen) and major drug developer Eli Lilly and Co. have discovered a gene mutation that may be a major breakthrough in cancer treatment.
Through a collaborative project, TGen and Eli Lilly scientists discovered a recurring mutation of the AKT1 gene in breast, colorectal, and ovarian cancers. The findings are to be published in the online version of Nature.
The study, which was led by Dr. John Carpten, senior investigator and director of TGen’s Integrated Cancer Genomics Division, involved collaboration between TGen scientists and Eli Lilly researchers in Singapore and Indianapolis.
The findings could help researchers develop specific drugs to target different types of cancer, marking a significant step toward personalizing medicine.
“This is a classic example of why we’re investing in the biosciences and the type of return we can get,” said Jon McGarity, former president and chief executive of Arizona BioIndustry Association. “This is a giant step forward.”
For more information:
“TGen, Lilly scientists’ discover of gene mutation could be cancer breakthrough,” Business Journal, 07/04/2007
TGen news release, 07/04/2007